Skip to content
The Injury Atlas
CYST

Hemorrhagic Cystitis

Bleeding inflammation of the bladder urothelium — classically acrolein injury from the oxazaphosphorines (prevented by mesna), but also reported as immune-related, intravesical-chemical, or radiation-recall injury.

15agents

Where it strikes

Bladder / Urothelium

Urine storage (outflow, not a nephron segment)

See it on the nephron

Agents’ overall severity

Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.

Severe· 4Moderate· 2Mild· 9

Agents’ overall reversibility

Often irreversible· 2Partially reversible· 3Variable· 2Reversible· 8
Does the kidney recover? Cross-drug outcomes

Agents’ onset window

How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.

Hyperacute (<24 h)· 2Acute (days)· 3Subacute (weeks)· 2Delayed (weeks–months)· 5Variable· 3

Real-world reporting for this lesion

FAERS across all lesions →

How disproportionately hemorrhagic cystitis is reported for each agent in FAERS, against every other drug (reporting odds ratio, 95% CI; a signal needs the lower bound above 1, on at least 50 total reports for the agent) — a spontaneous-reporting signal, not incidence or proven causation. FAERS carries reporting and indication biases and has no denominator.

15Corroborated

Documented in the atlas profile and carrying a FAERS signal — the strongest claim the atlas makes.

0Documented, FAERS-silent

Documented in a profile with no reporting signal. Mostly expected: naming this lesion on a report can require a biopsy, or the agent has too few reports to divide.

49Not attributable

A real reporting signal that is not evidence for this drug-lesion pair: no MedDRA term names it, the naming subset asked alone came back flat, or the 2026-08 review attributed the reporting to the population, co-therapy, or class-level literature.

18Reported by name

The terms that name this lesion are disproportionate, but no profile documents it for that agent. Most are echoed by a sibling agent in the same class. Leads for review, never lesions the atlas claims.

Order
  1. PentostatinPurine analog (ADA inhibitor) · FAERS only20.58 (14.48–29.26) · n=33 Reporting signal.
  2. CabazitaxelTaxane12.50 (10.60–14.74) · n=148 Reporting signal.
  3. BusulfanAlkylator · FAERS only10.31 (9.47–11.23) · n=554 Reporting signal.
  4. Mitomycin CAntitumor antibiotic9.31 (7.74–11.20) · n=116 Reporting signal.
  5. FludarabinePurine analog · FAERS only6.73 (6.30–7.19) · n=911 Reporting signal.
  6. TeniposidePodophyllotoxin (topo II) · FAERS only6.56 (3.26–13.21) · n=8 Reporting signal, fragile (few reports).
  7. BicalutamideNonsteroidal antiandrogen · FAERS only6.14 (5.50–6.86) · n=323 * Reporting signal, on terms consistent with the lesion rather than naming it.
  8. PenpulimabPD-1 immune checkpoint inhibitor · FAERS only5.91 (1.46–23.99) · n=2 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
  9. ClofarabinePurine analog · FAERS only5.57 (4.13–7.51) · n=44 Reporting signal.
  10. ThiotepaAlkylator5.56 (4.81–6.42) · n=187 Reporting signal.
  11. Tisotumab vedotinAntibody-drug conjugate (tissue factor/MMAE) · FAERS only5.45 (3.33–8.94) · n=16 Reporting signal.
  12. AvelumabAnti-PD-L1 antibody · FAERS only3.63 (2.72–4.86) · n=46 * Reporting signal, on terms consistent with the lesion rather than naming it.
  13. SelpercatinibRET inhibitor · FAERS only3.53 (2.13–5.88) · n=15 * Reporting signal, on terms consistent with the lesion rather than naming it.
  14. CyclophosphamideOxazaphosphorine alkylator3.47 (3.33–3.63) · n=2,115 Reporting signal.
  15. IfosfamideOxazaphosphorine alkylator2.82 (2.46–3.23) · n=211 Reporting signal.
  16. GefitinibEGFR TKI2.68 (2.16–3.32) · n=84 Reporting signal.
  17. MitoxantroneAnthracenedione2.46 (1.88–3.22) · n=54 Reporting signal.
  18. DocetaxelTaxane2.28 (2.09–2.48) · n=539 Reporting signal.
  19. GemcitabineNucleoside analog1.60 (1.43–1.79) · n=302 Reporting signal.
  20. CarboplatinPlatinum agent1.59 (1.48–1.71) · n=722 Reporting signal.
  21. DoxorubicinAnthracycline1.58 (1.45–1.72) · n=535 Reporting signal.
  22. AtezolizumabAnti-PD-L1 antibody1.57 (1.36–1.81) · n=192 Reporting signal.
  23. PaclitaxelTaxane1.44 (1.32–1.57) · n=509 Reporting signal.
  24. CisplatinPlatinum agent1.42 (1.28–1.57) · n=392 Reporting signal.
  25. PembrolizumabPD-1 checkpoint inhibitor1.24 (1.13–1.37) · n=414 Reporting signal.

reporting odds ratio (log) — no signal left of the dashed line at 1.0

All 15 agents documented with CYST in the atlas are shown whether or not FAERS flags them, plus the 67 agents FAERS flags that the atlas does not document (marked “FAERS only”; the strongest 10 until you show all). 82 carry a reporting signal (filled dot: 95% CI lower bound above 1, on at least 50 reports for the agent); a signal on fewer than 10 reports of the disorder is hollow, on a dashed whisker. Grey marks are ratios that do not clear it. Signals are listed first, each group by ROR; * a signal carried by terms consistent with the lesion, not naming it. n = reports of the disorder for the agent. openFDA FAERS, as of 2026-11-15. A reporting signal, not incidence or causation, and no signal is not evidence of safety. Layout after the single-event rankings of Klomjit, Gupta et al.

Management approach

Full framework →

Prevent with mesna and hydration; this is an outflow (bladder) toxicity, not nephron injury.

Drug-level levers

  • Hold further dosing for significant hemorrhagic cystitis.
  • Co-administer mesna with ifosfamide and high-dose cyclophosphamide.

Pharmacologic toolkit

  • Mesna — Binds acrolein in the urine; standard prophylaxis with the oxazaphosphorines.
  • Hydration / bladder irrigation — Forced diuresis; continuous bladder irrigation for established hemorrhagic cystitis.

When to biopsy

Not a kidney-biopsy lesion; cystoscopy for severe or refractory bladder bleeding.

Monitoring

  • · Urinalysis for hematuria
  • · Symptoms of cystitis

Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.

Also associated

14

Agents that cause hemorrhagic cystitis as a secondary pattern alongside a different signature lesion.

CisplatinAcute — creatinine peaks ~day 4–7; magnesium wasting can persist for months.AKI (creatinine up more than 25% within 30 days of the first cycle) in 31.5% of 821 adults across tumor types — a cohort restricted to patients who survived at least 5 years (Latcha 2016, PMID 27073199). Hypomagnesemia in up to 90% if no corrective measures are taken (Lajer 1999, PMID 10212589).SevereIfosfamideAcute tubulopathy during therapy; chronic Fanconi/CKD can emerge months–years later.Subclinical tubular dysfunction is common while overt Fanconi is not, and the gap is the point. Prospectively, high-dose ifosfamide in children and young adults was associated with a 4% incidence of Fanconi-like syndrome, though every patient showed acute, reversible subclinical nephrotoxicity (Ho 1995, PMID 8625085). In 183 children investigated prospectively at least 5 years out — none of whom received any platinum, so the toxicity is attributable — the tubular threshold for phosphate was reduced in 24% and glycosuria detected in 37%, yet glycosuria exceeded 0.5 g/24 h in only 5%, bicarbonate and calcium were normal in every patient, and 89.5% had normal tubular function overall at a median 10 years. GFR was abnormal in 21.5%. Ifosfamide dose and time since therapy both predicted tubulopathy. Rates elsewhere span 0% to 84% depending on the definition and cohort used, so a single figure is only meaningful with its threshold attached.SevereGemcitabineDelayed — months of cumulative exposure.Estimates span three orders of magnitude by ascertainment. The only figure with a real denominator is the manufacturer safety-database review: 12 cases against 78,800 patient exposures, a crude 0.015% (range 0.008–0.078%). The product characteristics give 0.01%. Against that, a single center reported 2.7% — four of its five cases on nab-paclitaxel/gemcitabine, where a pharmacokinetic interaction is suspected. Historically high mortality: of 23 cases with reported outcome in the literature tally, 11 died within a few weeks, death directly attributed to HUS in two.SevereMitomycin CDelayed — after cumulative dosing, sometimes after therapy ends.Dose-dependent, generally 4–15%; nearly every case in the landmark 85-patient registry had received a cumulative total dose above 60 mg. >50% historical mortality.SevereAtezolizumabTypically weeks to a few months after initiation (median time to checkpoint-inhibitor AKI is on the order of 3-4 months, characteristically later than classic drug AIN).Across the checkpoint-inhibitor class, any acute kidney injury occurs in roughly 15-17% of treated patients in cohort studies, while clinically significant immune-related AKI (most often acute interstitial nephritis) affects a smaller subset (commonly a few percent). Meta-analysis suggests anti-PD-L1 agents like atezolizumab carry somewhat lower AKI risk than anti-PD-1 agents; PD-L1-specific rates are not precisely separated. A separate real-world cohort of 1,037 ICI-treated patients supplies the drug-attributable denominator this class otherwise lacks: 18.2% developed AKI of any cause, but only 3.6% (37 patients) had AKI attributed to the checkpoint inhibitor itself — a class figure, not an atezolizumab-specific one.ModeratePembrolizumabDelayed and highly variable, typically weeks to months after initiation; multicenter cohorts reported median onsets around 14-16 weeks. Can occur after a single dose or after many months, and may recur on rechallenge.In real-world cohorts of patients receiving immune checkpoint inhibitors, any AKI is common (roughly 16-18%), but AKI attributable to the checkpoint inhibitor itself (ICPi-AKI) is less frequent. A single-center cohort reported AKI in 16.5% of ICI-treated patients with checkpoint-attributable nephrotoxicity in a minority, while a larger real-world study found ICPi-AKI in about 3.6%. Acute interstitial nephritis is the dominant biopsy lesion (>80% in the largest multicenter series). These figures are pooled across PD-1/PD-L1/CTLA-4 agents rather than pembrolizumab-specific.ModerateCarboplatinAcute when it occurs (high-dose regimens).Clinically significant nephrotoxicity uncommon at standard doses; emerges mainly at high/myeloablative doses.MildCyclophosphamideHyponatremia within hours; cystitis acute.Dose-related hyponatremia (not reliably quantified); hemorrhagic cystitis ~5–20%, lower with mesna prophylaxis. Reported rate: hyponatremia in 52% — 69 adults who received high-dose cyclophosphamide therapy at a single center 2010-2014 (retrospective cohort (Bonella 2017, PMID 29890094).MildDoxorubicinSubacute in models (over weeks); clinical events rare and variable.Adriamycin nephropathy is the canonical rodent model of podocyte injury and focal segmental glomerulosclerosis (FSGS); clinically significant glomerular disease from therapeutic dosing in patients is rare and largely case-level. Separately, doxorubicin — especially the pegylated liposomal formulation — is an increasingly recognized but underreported cause of kidney-limited thrombotic microangiopathy (a vascular/endothelial lesion), described in biopsy-proven case reports and drug-induced-TMA series.MildGefitinibWeeks to months after initiation in reported cases; proteinuria resolves over weeks to months after stopping the drug.Nephrotic syndrome (minimal-change disease and secondary membranous nephropathy patterns) and rare acute renal failure are reported only as isolated cases; not quantified in clinical-trial datasets.MildPaclitaxelInfusion reactions occur during or shortly after administration (typically first/second exposure); any prerenal AKI follows the hemodynamic instability.Paclitaxel has low direct nephrotoxicity. Hypersensitivity/infusion reactions - historically attributed to the Cremophor EL (polyoxyethylated castor oil) vehicle via complement activation, with newer evidence for IgE-mediated reactions - and associated fluid shifts can transiently compromise renal perfusion, but structural kidney injury is uncommon and not well quantified.MildDocetaxelFluid retention develops cumulatively (often after several cycles / cumulative dose); hypersensitivity reactions occur during infusion.Docetaxel has low direct renal toxicity. Its characteristic fluid-retention syndrome (peripheral edema, effusions, weight gain) reflects increased capillary permeability rather than tubular injury; AKI directly attributable to docetaxel is uncommon and not well quantified, and the drug has been used successfully even in kidney-transplant recipients.MildCabazitaxelAKI follows intercurrent gastrointestinal or infectious complications during treatment cycles.Cabazitaxel has low direct nephrotoxicity; AKI is uncommon and usually mediated by gastrointestinal losses (diarrhea, occurring in a substantial minority), neutropenic sepsis, or hemodynamic instability rather than direct tubular toxicity. In real-world safety data, grade >=3 diarrhea and febrile neutropenia each occur in roughly 5% of patients. A drug-specific renal AKI rate is not well established.MildMitoxantroneTumor lysis hours to days post-infusion.Direct nephrotoxicity is low and not quantified; the principal renal risk is tumor lysis syndrome when used in bulky/rapidly proliferating hematologic malignancies. Benign blue-green discoloration of urine/sclera is expected (the anthracenedione chromophore), not injury.Mild